Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies. 2011

Philipp Kiewe, and Martin Neumann, and Thomas Wagner, and Sepp Seyfert, and Heike Albrecht, and Eckhard Thiel, and Agnieszka Korfel
Department of Hematology, Oncology and Transfusion Medicine, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Hindenburgdamm 30/31, 12200 Berlin, Germany. philipp.kiewe@charite.de

OBJECTIVE The aim of this study was to examine the penetration of ifosfamide (IFO) and 4-hydroxy-ifosfamide (4-OH-IFO) into the CSF of human adults and to evaluate the influence of blood-CSF barrier (BCB) function. METHODS In 12 adult patients with a malignant CNS disease treated with IFO 1,300-2,000 mg/m(2)/d as a 3-hour intravenous infusion, 17 CSF samples were collected within 10 min after the end of IFO infusion. In 8 of these patients, the CSF was obtained in up to 5 sequential 2-ml portions to detect a potential caudocranial concentration gradient. Additionally, blood was collected before treatment and immediately following IFO infusion. RESULTS IFO was detected in all 17 CSF samples at a median concentration of 79.24 μmol/l (39.27-176.73) and a median CSF/plasma ratio of 0.38 (0.18-0.72). 4-OH-IFO was detected in 11 CSF samples from 7 patients at a median concentration of 4.1 μmol/l (2.44-36.03) and a median CSF/plasma ratio of 3.07 (0.62-29.12). 4-OH-IFO was undetectable in 6 CSF samples from 5 patients and in one plasma sample. Both CSF drug concentrations and their CSF/plasma quotients neither correlated with steroid comedication nor with albumin quotients (QAlb). CONCLUSIONS Both IFO and 4-OH-IFO can penetrate into the CSF of human adults without a correlation to CSF turnover. In contrast to IFO, 4-OH-IFO CSF penetration is not reliable with levels ranging between undetectable and exceeding those in the corresponding plasma.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010539 Permeability Property of membranes and other structures to permit passage of light, heat, gases, liquids, metabolites, and mineral ions. Permeabilities
D001812 Blood-Brain Barrier Specialized non-fenestrated tightly-joined ENDOTHELIAL CELLS with TIGHT JUNCTIONS that form a transport barrier for certain substances between the cerebral capillaries and the BRAIN tissue. Brain-Blood Barrier,Hemato-Encephalic Barrier,Barrier, Blood-Brain,Barrier, Brain-Blood,Barrier, Hemato-Encephalic,Barriers, Blood-Brain,Barriers, Brain-Blood,Barriers, Hemato-Encephalic,Blood Brain Barrier,Blood-Brain Barriers,Brain Blood Barrier,Brain-Blood Barriers,Hemato Encephalic Barrier,Hemato-Encephalic Barriers
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Philipp Kiewe, and Martin Neumann, and Thomas Wagner, and Sepp Seyfert, and Heike Albrecht, and Eckhard Thiel, and Agnieszka Korfel
January 1983, European journal of clinical pharmacology,
Philipp Kiewe, and Martin Neumann, and Thomas Wagner, and Sepp Seyfert, and Heike Albrecht, and Eckhard Thiel, and Agnieszka Korfel
January 2023, Chemotherapy,
Philipp Kiewe, and Martin Neumann, and Thomas Wagner, and Sepp Seyfert, and Heike Albrecht, and Eckhard Thiel, and Agnieszka Korfel
January 1988, Epilepsia,
Philipp Kiewe, and Martin Neumann, and Thomas Wagner, and Sepp Seyfert, and Heike Albrecht, and Eckhard Thiel, and Agnieszka Korfel
April 1988, Cancer research,
Philipp Kiewe, and Martin Neumann, and Thomas Wagner, and Sepp Seyfert, and Heike Albrecht, and Eckhard Thiel, and Agnieszka Korfel
September 1981, British journal of clinical pharmacology,
Philipp Kiewe, and Martin Neumann, and Thomas Wagner, and Sepp Seyfert, and Heike Albrecht, and Eckhard Thiel, and Agnieszka Korfel
November 1998, Antimicrobial agents and chemotherapy,
Philipp Kiewe, and Martin Neumann, and Thomas Wagner, and Sepp Seyfert, and Heike Albrecht, and Eckhard Thiel, and Agnieszka Korfel
August 1976, Antibiotiki,
Philipp Kiewe, and Martin Neumann, and Thomas Wagner, and Sepp Seyfert, and Heike Albrecht, and Eckhard Thiel, and Agnieszka Korfel
November 1976, Antibiotiki,
Philipp Kiewe, and Martin Neumann, and Thomas Wagner, and Sepp Seyfert, and Heike Albrecht, and Eckhard Thiel, and Agnieszka Korfel
September 1984, Antimicrobial agents and chemotherapy,
Philipp Kiewe, and Martin Neumann, and Thomas Wagner, and Sepp Seyfert, and Heike Albrecht, and Eckhard Thiel, and Agnieszka Korfel
July 1997, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!